Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ZNTL |
---|---|---|
09:32 ET | 5838 | 3.735 |
09:34 ET | 500 | 3.73 |
09:36 ET | 300 | 3.77 |
09:38 ET | 3549 | 3.76 |
09:39 ET | 2628 | 3.8 |
09:41 ET | 3896 | 3.76 |
09:43 ET | 1413 | 3.75 |
09:45 ET | 400 | 3.75 |
09:48 ET | 1100 | 3.78 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Zentalis Pharmaceuticals Inc | 262.4M | -1.4x | --- |
Corbus Pharmaceuticals Holdings Inc | 258.8M | -3.7x | --- |
Rezolute Inc | 270.2M | -3.7x | --- |
Zura Bio Ltd | 253.2M | -8.2x | --- |
ESSA Pharma Inc | 275.5M | -9.9x | --- |
Black Diamond Therapeutics Inc | 249.2M | -2.8x | --- |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $262.4M |
---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.70 |
EPS | $-2.75 |
Book Value | $6.18 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 6.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -543.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.